Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (SGMO) Stock Overview
Explore Sangamo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
70.4M
P/E Ratio
-0.54
EPS (TTM)
$-0.38
ROE
66.86%
SGMO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Sangamo Therapeutics, Inc. (SGMO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.22, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.54 and a market capitalization of 70.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.